Related Experiment Video
Updated: Aug 21, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
[Study on the relationship between the polymorphism of P22phox C242T, vitamin E and coronary heart disease]
Mei'an He1, Changzheng Jiang, Hongyan Zheng
1Institute of Occupational Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Objective:
To study the C242T mutation frequency of the cytochrome b4 (P22phox) in Chinese and to further ascertain the relationship between the polymorphism of P22Phphox C242T, vitamin E and coronary heart disease (CHD).
Methods:
151 patients with CHD and 254 controls were genotyped for the P22phox C242T polymorphism by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, the concentrations of the vitamin E in plasma were measured by reversed-phase high performance liquid chromatography (RP-HPLC).
Results:
The study shows that the allele frequency of C and T is 92.72% and 7.28% in the whole people and the polymorphism of P22phox C242T is associated with CHD in Chinese. Vitamin E is protective against CHD and there is effect on the progress of CHD in the interaction of the polymorphism of P22phox C242T and vitamin E. By stepwise Logistic regression analysis the results suggest that male, smoking, non-drinking, hypertension, diabetes, stroke of parents and low concentration of vitamin E in plasma are the possible risk factors in CHD.
Conclusion:
The polymorphism of P22phox C242T is associated with CHD in Chinese. Vitamin E is protective against CHD and there is effect on the progress of CHD in the interaction of the polymorphism of P22phox C242T and vitamin E.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Coronary Artery Disease I: Introduction
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Acute Coronary Syndrome III: Diagnostic Studies